Myrthe Julia Ottenhoff

Myrthe Julia Ottenhoff

Auto-generated profile, based on publicly available information

Myrthe Julia Ottenhoff

BlinkLab Limited Perth Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
MOMyrthe J. Ottenhoff
Myrthe J. Ottenhoff
ARAndré B. Rietman
André B. Rietman
SMSabine E. Mous
Sabine E. Mous
EPEllen Plasschaert
Ellen Plasschaert
DGDaniela Gawehns
Daniela Gawehns
LHLeontine W. Ten Hoopen
Leontine W. Ten Hoopen
Purpose Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder associated with cognitive deficits. The NF1 cognitive phenotype is generally considered to be highly variable, possibly due to the observed T2-weighted hyperintensities, loss of heterozygosity, NF1-specific genetic modifiers, or allelic imbalance. Methods We investigated cognitive variability and assessed the contribution of genetic factors by performing a retrospective cohort study and a monozygotic twin case series. We included data of 497 children with genetically confirmed NF1 and an IQ assessment, including 12 monozygotic twin and 17 sibling sets. Results Individuals carrying an NF1 chromosomal microdeletion showed significant lower full-scale IQ (FSIQ) scores than individuals carrying intragenic pathogenic NF1 variants. For the intragenic subgroup, the variability in cognitive ability and the correlation of IQ between monozygotic NF1 twin pairs or between NF1 siblings is similar to the general population. Conclusions The variance and heritability of IQ in individuals with NF1 are similar to that of the general population, and hence mostly driven by genetic background differences. The only factor that significantly attenuates IQ in NF1 individuals is the NF1 chromosomal microdeletion genotype. Implications for clinical management are that individuals with intragenic NF1 variants that score <1.5–2 SD below the mean of the NF1 population should be screened for additional causes of cognitive disability.

28 September 2024 in Developmental Medicine & Child Neurology
Verified
Journal Article
Open access
MOMyrthe J. Ottenhoff
Myrthe J. Ottenhoff
SMSabine Mous
Sabine Mous
JCJesminne Castricum
Jesminne Castricum
ARAndré Bernard Rietman
André Bernard Rietman
OOOostenbrink Oostenbrink
Oostenbrink Oostenbrink
WTWalter Taal
Walter Taal
Aim: To find proof‐of‐principle evidence for short‐term treatment with lamotrigine to improve cognitive functioning of adolescents with neurofibromatosis type 1 (NF1).Method: This was a double‐blind, parallel‐group, randomized, placebo‐controlled clinical trial (the NF1‐EXCEL trial: Examining the Cognitive and Electrophysiological benefit of Lamotrigine in Neurofibromatosis type 1; Clinicaltrials.gov identifier NCT02256124), with the aim of enrolling 60 adolescents with NF1 aged 12 to 17 years 6 months. The short‐term study intervention was 200 mg of lamotrigine taken orally for 26 weeks. The primary outcome was performance IQ tested with the Wechsler Intelligence Scale for Children, Third Edition, complemented with secondary outcomes for visuospatial learning efficacy, visual perception, visual sustained attention, fine motor coordination, attention‐deficit/hyperactivity problems, and executive functioning.Results: We screened 402 adolescents with NF1, of whom 31 (eight females) entered the study. Complete‐case analysis showed no effect of lamotrigine on either performance IQ (−0.23, 95% CI −6.90 to 6.44) or most secondary outcomes. Visual sustained attention showed a trend towards better performance in the lamotrigine group (−0.81, 95% CI −1.67 to 0.04).Interpretation: Lamotrigine did not improve cognitive functioning in adolescents with NF1. The small treatment effects make it unlikely that a larger sample size could have changed this conclusion.

18 February 2020 in eneuro
Verified
Journal Article
Open access
PDF file
MOMyrthe J. Ottenhoff
Myrthe J. Ottenhoff
LKLianne C. Krab
Lianne C. Krab
YEYpe Elgersma
Ype Elgersma
Significance statement The HMG-CoA reductase inhibitors lovastatin and simvastatin have both been investigated in clinical trials designed to treat the cognitive deficits associated with neurodevelopmental disorders such as Neurofibromatosis type 1, Fragile X and autism. In a recent study, the therapeutic efficacy of lovastatin and simvastatin were compared in a Fragile X (Fmr1) mouse model. The authors concluded that lovastatin was superior to simvastatin in rescuing the Fmr1 phenotypes, and cautioned against considering simvastatin as treatment for neurodevelopmental disorders. We discuss these findings in the context of published literature and argue that more support is needed for this potentially far-reaching conclusion. We further provide recommendations to improve the translation of pre-clinical studies of cognitive disorders into the clinical domain.

9 November 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MOM. J. Ottenhoff
M. J. Ottenhoff
SDStéphanie Dijkhuizen
Stéphanie Dijkhuizen
AYA. C. H. Ypelaar
A. C. H. Ypelaar
NON. L. de Oude
N. L. de Oude
SKS. K. E. Koekkoek
S. K. E. Koekkoek
HBHenk-Jan Boele
Henk-Jan Boele
Individuals with Neurofibromatosis type 1 (NF1) experience a high degree of motor problems. The cerebellum plays a pivotal role in motor functioning and the NF1 gene is highly expressed in cerebellar Purkinje cells. However, it is not well understood to what extent NF1 affects cerebellar functioning and how this relates to NF1 motor functioning. Therefore, we subjected global Nf1+/− mice to a cerebellum-dependent associative learning task, called Pavlovian eyeblink conditioning. Additionally, we assessed general motor function and muscle strength in Nf1+/− mice. To our surprise, we found that Nf1+/− mice showed a moderately increased learning rate of conditioned eyeblink responses, as well as improved accuracy in the adaptive timing of the eyeblink responses. Locomotion, balance, general motor function, and muscle strength were not affected in Nf1+/− mice. Together, our results support the view that cerebellar function in Nf1+/− mice is unimpaired.

1 March 2012 in Pediatrics
Verified
Journal Article
Closed access
PDF file
MOMyrthe J. Ottenhoff
Myrthe J. Ottenhoff
RDRuben Dammers
Ruben Dammers
EKErwin J. O. Kompanje
Erwin J. O. Kompanje
DTDick Tibboel
Dick Tibboel
TJT. H. Rob de Jong
T. H. Rob de Jong
OBJECTIVE: In a worldwide debate on deliberately terminating the lives of newborns, proponents point at newborns with very severe forms of myelomeningocele (MMC) and their assumed suffering, claiming there are no effective means of alleviating their distress. Nevertheless, the degree of discomfort and pain in these newborns has never been assessed in a structured manner. METHODS: In a prospective cohort study, 28 consecutive newborns with MMC were included over a 5-year period and were followed up throughout their hospital stay for initial treatment. We created 2 disease severity groups on the basis of the Lorber criteria. The primary outcomes were discomfort and pain, assessed by simultaneously scoring 2 validated scales: the visual analog scale for pain and the Comfort Behavioral Scale for discomfort. These scores were coupled to a validated and evidence-based analgesia algorithm. RESULTS: Overall, discomfort related to pain was measured in 3.3% of the scores. This percentage differed little between the preoperative and postoperative periods and did not significantly differ between newborns with less severe MMC and severe MMC (3.9% vs 2.8%; P = .3). The mean dosage of paracetamol was 35 mg/kg per day (95% confidence interval: 32–39); the mean dosage of morphine was 0.9 μg/kg per hour (95% confidence interval: 0.6 –1.2). CONCLUSION Over the length of their hospital stays for initial treatment, all newborns with MMC presented with low levels of discomfort and pain independent of disease severity and time frame.

3 January 2026 in Autism Research
Verified
Journal Article
Open access
KGKayleigh Danielle Gultig
Kayleigh Danielle Gultig
CBCornelis P. Boele
Cornelis P. Boele
LRLotte E. M. Roggeveen
Lotte E. M. Roggeveen
TSTing Fang Soong
Ting Fang Soong
SSSeth Sherry
Seth Sherry
HBHenk-Jan Boele
Henk-Jan Boele
Differences in sensorimotor processing represent an important, yet underrecognized, feature of autism; typically assessed through subjective observations, which, although important, are susceptible to biases. To complement these observations, a more objective approach to assess sensorimotor function may be possible through reflex‐based neurobehavioral evaluations. The clinical application of these assessments has, however, been largely confined to laboratory settings. Thus, small sample sizes and inconsistent findings have made it challenging to understand how sensorimotor function differs in autism and whether it can be used as an objective biomarker for diagnostics. Here we present a novel smartphone‐based platform to conduct neurobehavioral evaluations by measuring facial and behavioral responses in at‐home environments. Through a multi‐center study, we explored the platform's ability to distinguish between children with and without autism. We enrolled 536 children aged 3–12 years. BlinkLab smartphone‐based assessments were successfully completed in 431 children (80.4%), including 275 with autism and 156 neurotypical children. We found that autistic children showed altered sensorimotor responses across multiple domains. These included reduced prepulse inhibition (PPI), stronger startle habituation over the course of a PPI test, more variable eyeblink responses to auditory stimuli and significant sensitization. Additionally, children with autism displayed more screen avoidance, postural instability, head movements, mouth openings, non‐syllabic vocalizations, horizontal pupil shifts, “side‐eyeing”, and variation in baseline eyelid opening. Exploratory analyses showed that these effects were largely independent of co‐occurring conditions. Notably, co‐occurrence did influence certain subdomains (e.g., PPI, mouth openings). These findings illustrate that smartphone‐based assessments can capture distinct sensorimotor profiles associated with autism in real‐world environments.